このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women (MEMO)

2026年9月2日 更新者:Darren Mays、Ohio State University Comprehensive Cancer Center
This is an online cross-sectional experimental survey study examining two cancer communication questions: 1) What features of social media messages communicating the breast cancer risks from alcohol consumption will motivate young adult women to drink less? and 2) Do message features differ in their persuasive effects based on young adult women's alcohol consumption behavior?

調査の概要

詳細な説明

This is an online cross-sectional experimental study to examine the effects of features of social media messages in young adult women ages 18-25 who drink alcohol based on valid, self-report outcomes. Within the survey, participants will be randomized to view messages in one of nine conditions in a 3x3 factorial design with baseline alcohol consumption as a within-participants factor to test the effects of social media message features (content, persuasive themes) on participant responses. We will also compare the effects of message features for young women who drink within recommended limits (1 drink/day or less on average) and those who exceed recommended drinking limits.

研究の種類

介入

入学 (推定)

900

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • The Ohio State University Comprehensive Cancer Center
        • 主任研究者:
          • Darren Mays, MPH, PhD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Assigned female at birth
  • Age 18-25
  • Report drinking alcohol at least once in the past 30 days
  • Registered in the United States as a member of the Prolific consumer research platform
  • Willing and able to complete procedures in English

Exclusion Criteria:

  • Assigned male at birth
  • Ages <18 or >25
  • Do not report drinking alcohol at least once in the past 30 days
  • Not registered in the U.S. as a member of the Prolific consumer research platform
  • Not willing or not able to complete procedures

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1: Risk Only + Industry Deception
Risk message content
Messages with information about alcohol industry deception
実験的:Arm 2: Risk Only + YAW Susceptibility
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
実験的:Arm 3: Risk Only + Mechanisms
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
実験的:Arm 4: Efficacy Only + Industry Deception
Messages with information about alcohol industry deception
Efficacy Message Content
実験的:Arm 5: Efficacy Only + YAW Susceptibility
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
実験的:Arm 6: Efficacy Only + Mechanisms
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content
実験的:Arm 7: Risk and Efficacy + Industry Deception
Risk message content
Messages with information about alcohol industry deception
Efficacy Message Content
実験的:Arm 8: Risk and Efficacy + YAW Susceptibility
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
実験的:Arm 9: Risk and Efficacy + Mechanisms
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Message Perceptions
時間枠:This assessment is administered immediately after participants view study messages on Day 1

We will assess message perceptions using a valid, reliable measure with six questions about whether participants thought the messages were worth remembering, grabbed their attention, and were informative, powerful, convincing, and meaningful. Responses are on a five-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree).

For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.

This assessment is administered immediately after participants view study messages on Day 1
Effect Perceptions
時間枠:This assessment is administered immediately after participants view study messages on Day 1
We will capture message effects perceptions using the abbreviated effects perceptions scale. Items include questions about how much the messages made them feel discouraged to drink alcohol, concerned about drinking alcohol, and made them feel that drinking alcohol is unpleasant on a scale from 1 (Strongly disagree) to 5 (Strongly agree). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Emotional Response
時間枠:This assessment is administered immediately after participants view study messages on Day 1
We will capture emotional responses to the messages using a valid, four item scale. Items are "This message made me angry; irritated; aggravated; and annoyed" with responses on a 5-point Likert scale from 1 (Not likely at all) to 5 (Extremely likely). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Counter-arguing
時間枠:This assessment is administered immediately after participants view study messages on Day 1
We will capture counter-arguing, a measure of whether participants cognitively refute messages, with a valid, three item scale that captures whether participants criticize messages, think of points that go against messages, and are skeptical of the messages. Responses are on a 5-point Likert scale ranging from 1 (Not at all) to 7 (Very much). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Lower values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Behavioral Intentions
時間枠:This assessment is administered immediately after participants view study messages on Day 1
Intentions to reduce alcohol consumption in the future will also be assessed with a valid, multi-item scale capturing whether participants will avoid drinking alcohol completely, reduce the number of occasions when they drink alcohol, and reduce the amount of alcohol they consume on drinking occasions with a 1 (Definitely Will Not) to 4 (Definitely Will) response scale. For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Darren Mays, MPH, PhD、The Ohio State University Comprehensive Cancer Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年6月30日

研究の完了 (推定)

2028年7月1日

試験登録日

最初に提出

2026年8月28日

QC基準を満たした最初の提出物

2026年9月2日

最初の投稿 (実際)

2026年9月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月3日

QC基準を満たした最後の更新が送信されました

2026年9月2日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • OSU-26048
  • R01CA311193-01 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data from self-report measures will be deposited in the Inter-university Consortium for Political and Social Research (ICPSR). ICPSR will make the research data from this project available to the broader social science research community as public-use data files. These files, in which direct and indirect identifiers have been removed to minimize disclosure risk, may be accessed directly through the ICPSR website.

IPD 共有時間枠

The research data from this project will be supplied to ICPSR at the time of publication of the relevant results or at the end of the project period, whichever is sooner, so that any issues surrounding the usability of the data can be resolved. Delayed dissemination may be possible. The Delayed Dissemination Policy allows for data to be deposited but not disseminated for an agreed-upon period (typically one year).

IPD 共有アクセス基準

After agreeing to Terms of Use, users with an ICPSR MyData account and an authorized IP address from a member institution may download the data, and non-members may purchase the files.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する